Beijing Foyou Pharma CO.,LTD

SHSE:601089 Stock Report

Market Cap: CN¥7.3b

Beijing Foyou PharmaLTD Past Earnings Performance

Past criteria checks 3/6

Beijing Foyou PharmaLTD has been growing earnings at an average annual rate of 19.2%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 0.3% per year. Beijing Foyou PharmaLTD's return on equity is 14.8%, and it has net margins of 15.3%.

Key information

19.2%

Earnings growth rate

11.5%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate0.3%
Return on equity14.8%
Net Margin15.3%
Last Earnings Update31 Mar 2024

Recent past performance updates

Investors Shouldn't Be Too Comfortable With Beijing Foyou PharmaLTD's (SHSE:601089) Earnings

Apr 08
Investors Shouldn't Be Too Comfortable With Beijing Foyou PharmaLTD's (SHSE:601089) Earnings

Recent updates

Investors Shouldn't Be Too Comfortable With Beijing Foyou PharmaLTD's (SHSE:601089) Earnings

Apr 08
Investors Shouldn't Be Too Comfortable With Beijing Foyou PharmaLTD's (SHSE:601089) Earnings

Revenue & Expenses Breakdown
Beta

How Beijing Foyou PharmaLTD makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:601089 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 243,3235081,314364
31 Dec 233,3404891,350353
30 Sep 233,3374871,428288
30 Jun 233,3274831,481270
31 Mar 233,3124671,496259
31 Dec 223,2404391,494238
30 Sep 223,1603851,484228
30 Jun 223,0593571,461204
31 Mar 222,9753401,446191
31 Dec 212,8383141,401177
31 Dec 202,5352631,342138
31 Dec 192,4252191,398169
31 Dec 182,0202001,094140

Quality Earnings: 601089 has a high level of non-cash earnings.

Growing Profit Margin: 601089's current net profit margins (15.3%) are higher than last year (14.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 601089's earnings have grown by 19.2% per year over the past 5 years.

Accelerating Growth: 601089's earnings growth over the past year (8.7%) is below its 5-year average (19.2% per year).

Earnings vs Industry: 601089 earnings growth over the past year (8.7%) exceeded the Pharmaceuticals industry -0.1%.


Return on Equity

High ROE: 601089's Return on Equity (14.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.